NO175964C - Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning - Google Patents

Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning

Info

Publication number
NO175964C
NO175964C NO880705A NO880705A NO175964C NO 175964 C NO175964 C NO 175964C NO 880705 A NO880705 A NO 880705A NO 880705 A NO880705 A NO 880705A NO 175964 C NO175964 C NO 175964C
Authority
NO
Norway
Prior art keywords
platinum
macromolecular
preparing
therapeutically active
complex composition
Prior art date
Application number
NO880705A
Other languages
English (en)
Other versions
NO880705L (no
NO880705D0 (no
NO175964B (no
Inventor
Anthony J Serino
Geoffrey W Henson
David A Schwartz
Donald H Picker
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of NO880705D0 publication Critical patent/NO880705D0/no
Publication of NO880705L publication Critical patent/NO880705L/no
Publication of NO175964B publication Critical patent/NO175964B/no
Publication of NO175964C publication Critical patent/NO175964C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Insulating Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO880705A 1987-02-25 1988-02-17 Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning NO175964C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/018,715 US4793986A (en) 1987-02-25 1987-02-25 Macromolecular platinum antitumor compounds

Publications (4)

Publication Number Publication Date
NO880705D0 NO880705D0 (no) 1988-02-17
NO880705L NO880705L (no) 1988-08-26
NO175964B NO175964B (no) 1994-10-03
NO175964C true NO175964C (no) 1995-01-11

Family

ID=21789419

Family Applications (1)

Application Number Title Priority Date Filing Date
NO880705A NO175964C (no) 1987-02-25 1988-02-17 Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning

Country Status (12)

Country Link
US (1) US4793986A (no)
EP (1) EP0280474B1 (no)
JP (1) JPS63284134A (no)
AT (1) ATE96679T1 (no)
AU (1) AU596774B2 (no)
CA (1) CA1305665C (no)
DE (1) DE3885317T2 (no)
DK (1) DK96588A (no)
IE (1) IE63003B1 (no)
NO (1) NO175964C (no)
NZ (1) NZ223549A (no)
ZA (1) ZA881077B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952676A (en) * 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
US4956454A (en) * 1984-06-27 1990-09-11 Johnson Matthey Plc Monoclonal antibody - platinum co-ordination compound complex
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
SU1685944A1 (ru) * 1988-06-06 1991-10-23 Институт Физической Химии Им.Л.В.Писаржевского Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
WO1990010709A2 (en) * 1989-03-14 1990-09-20 Board Of Regents Of The University Of Nebraska Monoclonal antibodies for metallic cations on small molecules
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
US5972656A (en) * 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
DK0722457T3 (da) * 1993-10-04 2002-04-22 Pasteur Institut Forbindelser, der modificerer den serotoninerge transmission, og diagnostisk og terapeutisk anvendelse af sådanne forbindelser
EP0692252B1 (en) * 1994-06-14 2001-04-04 "Raffinerie Tirlemontoise", société anonyme: Use of a composition containing inulin or oligofructose in cancer treatment
AU2701395A (en) * 1994-06-27 1996-01-19 General Hospital Corporation, The Graft co-polymer adducts of platinum (ii) compounds
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
DE69833487T9 (de) * 1997-06-12 2007-03-01 Innovata Plc, Ruddington Polymer-wirkstoff-konjugate zur behandlung von krebs
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6692734B2 (en) * 2000-01-04 2004-02-17 Access Pharmaceuticals, Inc. N,O-amidomalonate platinum complexes
US6800728B2 (en) 2000-03-22 2004-10-05 Solulink Biosciences, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20030082102A1 (en) * 2001-06-25 2003-05-01 Court Wayne S. Radioactive platinum complexes for cancer treatment
DE60323936D1 (de) 2002-01-14 2008-11-20 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
EP1534269B1 (en) 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
US7790150B2 (en) 2003-09-05 2010-09-07 The General Hospital Corporation Dual phase drug release system
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
WO2007126078A1 (ja) * 2006-04-27 2007-11-08 Onecell Inc. ヌクレオチド-遷移金属錯体触媒
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CN102307473A (zh) 2008-12-10 2012-01-04 摩萨纳医疗有限公司 可生物降解的生物相容性喜树碱-聚合物共轭物的药物制剂
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
NL2020120B1 (en) * 2017-12-19 2019-06-26 Linxis B V Methods for preparing cell targeting conjugates and conjugates obtainable by said methods
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
IL66338A (en) * 1982-07-15 1986-03-31 Yeda Res & Dev Anti-cancer drugs comprising platinum complexed antitumor immunoglobulins
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
IL67789A (en) * 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
US4673754A (en) * 1983-10-14 1987-06-16 Inco Alloys International, Inc. Platinum and palladium complexes
DE3582961D1 (de) * 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
IL73972A0 (en) * 1984-12-31 1985-03-31 Yeda Res & Dev Agents based on platinum compounds

Also Published As

Publication number Publication date
EP0280474A2 (en) 1988-08-31
NO880705L (no) 1988-08-26
EP0280474B1 (en) 1993-11-03
DE3885317T2 (de) 1994-03-03
DK96588D0 (da) 1988-02-24
DE3885317D1 (de) 1993-12-09
IE880498L (en) 1988-08-25
CA1305665C (en) 1992-07-28
EP0280474A3 (en) 1990-01-31
IE63003B1 (en) 1995-03-08
NO880705D0 (no) 1988-02-17
NZ223549A (en) 1989-10-27
ZA881077B (en) 1988-08-11
NO175964B (no) 1994-10-03
DK96588A (da) 1988-08-26
AU596774B2 (en) 1990-05-10
AU1213588A (en) 1988-09-01
US4793986A (en) 1988-12-27
ATE96679T1 (de) 1993-11-15
JPS63284134A (ja) 1988-11-21

Similar Documents

Publication Publication Date Title
DK96588D0 (da) Antitumirmiddel indeholdende makromolekylaere platinforbindelser
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
DK0532525T3 (da) Nye protein-polykationkonjugater
NL7611970A (nl) Werkwijze voor het bereiden van corticoide ste- roiden, werkwijze voor het bereiden van trime- thylsiloxysteroiden, werkwijze voor het berei- den van preparaten die deze verbindingen bevat- ten, alsmede de verkregen gevormde preparaten.
FI104234B1 (fi) Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon
HUT41390A (en) Process for preparing 3-cyan pyridine derivatives and pharmaceutical preparations comprising the same as active substance
AU557980B2 (en) Perfluorohydrocarbons as vehicles for drugs
NL175435C (nl) Werkwijze voor de bereiding van optisch aktieve aminozuurverbindingen.
RO72547A (ro) Procedeu pentru prepararea unor esteri 2',3,6'-triclor-4-cian-4'-benzoilureidodifenilici
HU177823B (en) Rodenticide composition containing n-alkyl-2,4-dinitro-6-trifluoromethyl-diphenyl-amine derivatives and process for producing the active agents
NL168880B (nl) Werkwijze voor het bereiden van bacterie-eiwit.
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
PT81093B (pt) Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor
BG31070A3 (bg) Метод за получаване на 11-дезокси-16-арил-сигма- тетранорпростагландини
NL7902117A (nl) Werkwijze voor de bereiding van een optisch aktieve alpha-cyano-alcohol-ether.
SU542766A1 (ru) Способ автоматического управлени процессом непрерывного выращивани микроорганизмов
NL7600614A (nl) Werkwijze voor het bereiden van cyclohexeenesters, werkwijze voor het bereiden van herbicide prepara- ten, alsmede de gevormde preparaten.
NL7607713A (nl) Werkwijze voor de bereiding van eiwitprodukten door kweken van monocellulaire micro-organismen.
NL181433C (nl) Werkwijze voor het bereiden van cyclo-1,3,2-oxazafosforylderivaten.
NL7605503A (nl) Werkwijze voor het bereiden van preparaten voor het reguleren van de plantegroei.
NL7600776A (nl) Werkwijze voor het bereiden van preparaten voor het reguleren van de plantegroei.
PT65122A (fr) Diamino-2,4 bromo-5 chloro-6 pyrimidines utilisables comme medicaments et procede pour preparation
GB1254948A (en) Antivirial substance
NL7602860A (nl) Werkwijze voor het bereiden van 1-hydroxy 2.2.2- -trichloorethaanthionofosfonzuurdialkylesters, alsmede de toepassing daarvan als insecticiden.
NO162466C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt 4-n-(3',5',-bis(n-pyrrolidinylmetyl)-4'-hydroksyanilino)-pyridin.